Reliable detection of (early) biomarkers of disease can mitigate – or even prevent – long-term damage from disease progression. We apply our understanding of the fundamental mechanisms of disease to identify tissue-specific (early) biomarkers for low-grade inflammation. The validation of our workflow resulted in the identification of key biomarkers for inflammation in liver and adipose tissue. In addition, we applied this workflow to identify biomarkers for fibrosis in MASH (pdf). The blood test that can analyse these biomarkers without a liver biopsy has been patented. TNO is now eager to apply this approach to identify key biomarkers for other diseases.